Aclaris Therapeutics (ACRS) Revenue (2017 - 2026)

Aclaris Therapeutics' Revenue history runs 10 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Revenue rose 37.18% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $8.4 million, a 52.94% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 58.19% from the prior year.
• Revenue improved to $2.0 million in Q1 2026 per ACRS's latest filing, from $1.3 million in the prior quarter.
• Across five years, Revenue topped out at $19.0 million in Q3 2022 and bottomed at $1.3 million in Q4 2025.
• The 5-year median for Revenue is $2.5 million (2023), against an average of $5.3 million.
• Across the five-year window, Revenue surged 1046.35% in 2022 and slumped 85.94% in 2025, its largest moves.
• Year by year, Revenue stood at $7.8 million in 2022, then surged by 126.62% to $17.6 million in 2023, then tumbled by 47.58% to $9.2 million in 2024, then slumped by 85.94% to $1.3 million in 2025, then jumped by 54.13% to $2.0 million in 2026.
• Per Business Quant, the three latest ACRS Revenue figures stand at $2.0 million (Q1 2026), $1.3 million (Q4 2025), and $3.3 million (Q3 2025).